CommLoan Achieves Nationwide Regulatory Approval Across All 50 States
Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services Company
Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services Company
Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Update
Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025
Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption
Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy
Windtree To Launch BNB Crypto Treasury Strategy With Agreement For $60 Million Investment Led By Build And Build Corp. With Up To $140 Million More In Follow On Subscriptions
Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure
Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel
Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025
Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025
Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics
Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules
Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product
Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company's Oncology Pipeline
WINT and Ferguson announce strategic collaboration to elevate water management and leak mitigation for real estate and construction
Windtree Announces the Addition of Leanne Kelly to Its Board of Directors
Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia
Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction
Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates
Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World
Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan
Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock
Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET
Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates
Windtree Announces New Additions and Changes to Its Board of Directors
Why Is Windtree Therapeutics (WINT) Stock Up 116% Today?
Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data
Windtree Therapeutics Regains Compliance with Nasdaq
What made Windtree Therapeutics stock tank 20% on Monday?
What made Windtree Therapeutics stock tank 20% on Monday?
Windtree Therapeutics Announces Reverse Stock Split
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company
Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China
Windtree Therapeutics Announces License Agreement with Lee's Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region
Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator
Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024
Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent
Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
Windtree to Present at the Sidoti Micro Cap Conference on November 16th
Windtree to Present at the ThinkEquity Conference on October 19th in New York City